Sonoma Pharmaceuticals Inc. sell nvestor
Start price
12.12.20
/
50%
€6.90
Target price
12.12.21
€3.00
Performance (%)
-8.48%
End price
26.06.21
€6.32
Summary
This prediction ended on 26.06.21 with a price of €6.32. With a performance of -8.48%, the SELL prediction by nvestor was trending in the right direction. nvestor has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sonoma Pharmaceuticals Inc. | -5.569% | -5.569% | -81.818% | -97.677% |
| iShares Core DAX® | -0.870% | -1.700% | 10.560% | 13.129% |
| iShares Nasdaq 100 | -5.561% | -3.604% | 34.335% | 39.856% |
| iShares Nikkei 225® | -6.138% | -7.732% | 16.215% | 0.044% |
| iShares S&P 500 | -3.141% | -2.011% | 24.534% | 39.859% |
According to nvestor what are the pros and cons of Sonoma Pharmaceuticals Inc. for the foreseeable future?
Pros
Cons
Risky Investment
Revenue decline > 20% expected
Decining EBIT margin than peer group
EBIT decline > 20% expected
overvalued
very negative Cash Flow expected
Very low/no dividend yield expected
Junk rating
Very little Investments for future growth
ROE lower than 5% per year
High challenges to pay loans and raise capital
High risks in the balance sheet
Deficits in Management
No Innovation
Very bad culture
No uniques
Dependend from few customers or products
Growths much slower than the competition
Sustainability is not important
High risks for its business
Mainly gamblers invest here
Nicheplayer
Very high cyclical dependencies
Unknown brand
Outdated or very high risk business model
Comments by nvestor for this prediction
In the thread Sonoma Pharmaceuticals, Inc. diskutieren
In the thread Trading Sonoma Pharmaceuticals, Inc.
Stopped prediction by nvestor for Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€8.05
30.05.20
30.05.20
€2.00
18.10.20
18.10.20
-14.91%
18.10.20
18.10.20
Risky Investment
Revenue decline > 20% expected
Decining EBIT margin than peer group
EBIT decline > 20% expected
